Free tool
FAERS Monitor: Jakafi Xr
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217180 or its brand name (Jakafi Xr, Ruxolitinib Phosphate). Reports on generic versions are filed under their own applications.
Reports
10,697
Serious
10,364
97% of reports
Hospitalization
4,097
Death reported
2,687
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use1,418
- drug ineffective1,035
- death787
- product use in unapproved indication781
- anaemia738
- pyrexia597
- pneumonia578
- thrombocytopenia562
- platelet count decreased532
- haemoglobin decreased511
- febrile neutropenia458
- splenomegaly446
- fatigue404
- diarrhoea403
- asthenia375
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 11 |
| 2013 | 14 |
| 2014 | 22 |
| 2015 | 53 |
| 2016 | 103 |
| 2017 | 209 |
| 2018 | 299 |
| 2019 | 333 |
| 2020 | 528 |
| 2021 | 1,104 |
| 2022 | 1,650 |
| 2023 | 1,844 |
| 2024 | 1,599 |
| 2025 | 1,653 |
| 2026 | 1,275 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,462 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| splenomegalySignal | 446 | 77.7 | 70.9 | 32,443 |
| febrile neutropeniaSignal | 458 | 13.7 | 12.5 | 5,342 |
| thrombocytopeniaSignal | 562 | 9.9 | 9.2 | 4,504 |
| platelet count decreasedSignal | 532 | 9.9 | 9.1 | 4,226 |
| haemoglobin decreasedSignal | 511 | 9.8 | 9.0 | 4,043 |
| anaemiaSignal | 738 | 7.6 | 7.1 | 4,270 |
| product use in unapproved indicationSignal | 781 | 6.2 | 5.8 | 3,440 |
| pneumoniaSignal | 578 | 3.5 | 3.2 | 1,052 |
| pyrexiaSignal | 597 | 3.4 | 3.1 | 1,022 |
| off label useSignal | 1,418 | 3.2 | 3.0 | 2,216 |
| asthenia | 375 | 2.0 | 1.8 | 179 |
| death | 787 | 1.8 | 1.7 | 289 |
| drug ineffective | 1,035 | 1.5 | 1.5 | 211 |
| diarrhoea | 403 | 1.2 | 1.1 | 17 |
| fatigue | 404 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.